Latanoprost Ingen Pharma (Latanoprost)

• Latanoprost is used in the management of ocular conditions that require reduction of intra‑ocular pressure.
• Primary open-angle glaucoma: lowers intra‑ocular pressure to slow visual field loss.
• Ocular hypertension: reduces pressure to prevent progression to glaucoma.
• Secondary open-angle glaucoma (including pseudoexfoliative glaucoma): provides pressure reduction similar to primary forms.

• Latanoprost binds to prostaglandin F (FP) receptors in the ciliary muscle, activating the uveoscleral outflow pathway. This increases the drainage of aqueous humor through the uveoscleral route, thereby decreasing intra‑ocular pressure and helping to preserve optic nerve function.

Latanoprost may cause ocular and peri‑ocular changes, most of which are mild and reversible.

Common Side Effects

• Eye redness: mild conjunctival hyperemia.
• Increased eyelash growth: longer, thicker lashes.
• Iris darkening: gradual brownish pigmentation.
• Eye irritation or foreign body sensation.
• Blurred vision: transient after instillation.
• Periocular skin darkening: mild hyperpigmentation.

Serious or Rare Side Effects

• Uveitis or severe eye inflammation.
• Allergic reactions: swelling, itching, or rash.
• Macular edema: fluid accumulation in the retina.
• Ocular pain: persistent discomfort.
• Vision loss: rare but severe impairment.
• Severe hypersensitivity: anaphylactic response.

• Before using Latanoprost, consider the following safety measures.
• Pregnancy: safety not established; avoid unless benefit outweighs risk.
• Breastfeeding: unknown excretion; use with caution.
• Active ocular infection: contraindicated until infection resolves.
• Intra‑ocular pressure monitoring: regular checks recommended to assess efficacy.
• Contact lens wearers: remove lenses before instillation and wait before reinserting.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents; monitor accordingly.

Major Interactions (Avoid)

• Non‑steroidal anti‑inflammatory eye drops: may diminish pressure‑lowering effect.
• Concurrent prostaglandin analogs: risk of additive ocular side effects.
• Systemic prostaglandin analogs: potential additive pressure reduction.
• Alpha‑adrenergic agonist eye drops: may antagonize Latanoprost efficacy.

Moderate Interactions (Monitor Closely)

• Beta‑blocker eye drops: monitor intra‑ocular pressure for additive effect.
• Carbonic anhydrase inhibitor eye drops: possible enhanced pressure reduction.
• Systemic carbonic anhydrase inhibitors: watch for excessive IOP lowering.